Literature DB >> 15685641

Parametric modelling of cost data: some simulation evidence.

Andrew Briggs1, Richard Nixon, Simon Dixon, Simon Thompson.   

Abstract

Recently, commentators have suggested that the distributional form of cost data should be explicitly modelled to gain efficiency in estimating the population mean. We perform a series of simulation experiments to evaluate the usual sample mean and the mean estimator of a lognormal distribution, in the context of both theoretical distributions and three large empirical datasets. The sample mean is always unbiased, but is somewhat less efficient when the population distribution is truly lognormal. However the lognormal estimator can perform appallingly when the true distribution is not lognormal. In practical situations, where the true distribution is unknown, the sample mean generally remains the estimator of choice, especially when limited sample size prohibits detailed modelling of the cost data distribution. Copyright (c) 2005 John Wiley & Sons, Ltd.

Mesh:

Year:  2005        PMID: 15685641     DOI: 10.1002/hec.941

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  28 in total

Review 1.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.

Authors:  Jeffrey S Hoch; Carolyn S Dewa
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Value of information and pricing new healthcare interventions.

Authors:  Andrew R Willan; Simon Eckermann
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

4.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

5.  Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.

Authors:  Mónica Hernández Alava; Allan Wailoo; Stephen Pudney; Laura Gray; Andrea Manca
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

6.  Health care costs and their predictors of inflammatory bowel diseases in Germany.

Authors:  Anne Prenzler; Bernd Bokemeyer; J-Matthias von der Schulenburg; Thomas Mittendorf
Journal:  Eur J Health Econ       Date:  2010-10-22

7.  Bayesian modelling of healthcare resource use in multinational randomized clinical trials.

Authors:  Aline Gauthier; Andrea Manca; Susan Anton
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Costing and cost analysis in randomized controlled trials: caveat emptor.

Authors:  Daniel Polsky; Henry Glick
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure.

Authors:  Gregory A Nichols; Anastasia Ustyugova; Anouk Déruaz-Luyet; Maureen O'Keeffe-Rosetti; Kimberly G Brodovicz
Journal:  J Am Soc Nephrol       Date:  2020-06-02       Impact factor: 10.121

Review 10.  Review of statistical methods for analysing healthcare resources and costs.

Authors:  Borislava Mihaylova; Andrew Briggs; Anthony O'Hagan; Simon G Thompson
Journal:  Health Econ       Date:  2010-08-27       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.